Skip to main content

BSE Award For “Best Return To Investors” at 5th Annual Pharmaceutical Leadership Awards 2012 Intensifies


Aanjaneya Lifecare, Divis Laboratories, TTK Healthcare, Ajanta Pharma in the race for the prestigious title as India votes to choose the company which has maximized their Returns on Investments

Sept 13, 2012: Pharrmaleaders, Asia’s biggest title in healthcare communications is gearing up to choose the top Pharmaceutical & Biotech Companies for their dramatic & significant accomplishments in their respective field at the 5th Annual Pharmaceutical Leadership Awards 2012 in as many as 33 categories, the biggest & coveted title that India is anxiously looking at is the Category that has made investors & stakeholder happy in the stock market.

Organized in association with BSE, Pharmexcil, IBEF & Ministry of Industry & Commerce, Government of India, the coveted  & prestigious title BSE  Award for the Best Return to Investors 2012 will be presented by Shri K. Shankaranarayan, His Excellency, Governor of Maharashtra on Friday 21st September at Hotel Hilton Mumbai International Airport amidst the presence of the veterans & who’s who’s of the Asia’s top Healthcare Leaders, Pharma Academia, Ministers, Policy Makers, Social Entrepreneurs & Medical Practioners.

More than top 200 professionals of the Industry are expected to attend the much awaited Leadership Event with the representation of Overseas Companies.

Speaking on the Award Nomination, Satya Brahma, Chairman of the Juries & Editor-In-Chief of Pharmaleaders said “This category has attracted tremendous attention in the stock market, Pharma Companies & in the general public as corporate ethics, Corporate Sustainability Model are the norms of the day & with so much of scrutiny by the regulators, BSE Award for the Best Return to the Investors will be a tight contest”.               

Of late there are many Midcaps in Healthcare doing exceedingly well. With macro economic conditions being difficult and most sectors not doing well, the market is chasing all growth-oriented companies in the defensive sectors of FMCG and now Pharma stocks.

Given the limited opportunity in the market, the Street has now turned to pharma stocks to capture growth and value. Most pharma companies with decent growth performance have witnessed a rally in its stock. 32% of the total 148 listed pharma stocks have flared up to new or 52-week highs in the last one month. The Indian pharma market is growing at 16-18%. Most Indian companies earn substantial revenues from outside by selling low-cost generic drugs in regulated markets. The industry is growing at an average rate of 20-22%.

About the Companies Nominated for BSE Award for “Best Return To Investors”

Dr Kannan Vishwanath led Aanjaneya Lifecare which specializes in niche segments has a strong presence in API and formulation business and has bulk drug manufacturing facility at Mahad and a finished dosage forms unit near Pune. It is one of the largest contract manufacturers of codeine-based cough syrups in India and exclusively makes Codorex brand of Zydus Cadilla and Codilite tablets among others. It recently raised around Rs 117 crore through an initial public offering (IPO). It acquired recentlyApex Drugs and Intermediates (ADI), a Hyderabad-based integrated active pharmaceutical ingredient (API) and intermediate company, for Rs.250 crore, including debt of Rs.185 crore and equity dilution of Rs.65 crore.

Divi’s Laboratories has earned a consolidated total income of Rs.722 crores for the 4th Quarter of the year 2011-12 as against a total income of Rs.480 crores during the corresponding quarter last year, reflecting a growth of 50%. Established in the year 1990, with Research & Development as its prime fundamental, Divis  Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

Purushottam B. Agrawal Led Ajanta Pharma is a specialty pharmaceutical company engaged in the development, manufacture and commercialization of pharmaceutical products. We employ over 3,500 people worldwide and our products are sold in over 30 countries. Ajanta operates with 5 state-of-the art manufacturing facilities that produce high quality pharmaceutical products. We focus on commercializing unique generic products and pioneering synergistic combination products in the therapeutic areas of anti- malarial, cardiology, dermatology, gastroenterology, musculoskeletal, ophthalmology and respiratory is also doing quite well.

Chennai based TTK Healthcare manufactures calcium supplements, haematinics, cervical dilators, thrombolytic agents, rejuvenators, multimineral supplements, liver correctives and pain management products.Besides being the first Pharmaceutical Company in India to be awarded the ISO certification by BIS, TTK Healthcare was also the first to launch technology-driven life-saving products like Urokinase and Dopamine. The Company has also developed medicines like Lactare based on Ayurveda - the ancient traditional system of medicine.

About 5th Annual Pharmaceutical Leadership Awards 2012.
Pharmaceutical Business Leadership Award Nominations 2012 has been carefully selected in 33 categories with several new entrants making it to the top category & big league as a result of their rising market presence. While the traditional Award Nominations have remained, some more categories have been created by the juries to give justice to the young companies & Leaders, further a great emphasis has been given to some of the unsung heroes & their innovative growth Stories. Pharmaleaders has taken every possible steps to keep the award nominations credible & newsworthy. While more than 500 top houses have been honored with their names featuring in Annual Reports & international platforms, Pharmaceutical Leadership Business Leadership Awards are widely perceived to be most credible & independent & free from political interference. The three tier judging mechanism allows each nominee to undergo a public scrutiny first by the SMS, Email & than the eminent Juries will decide the fate of achievers tonight. In a significant development, Pharmaleaders has introduced a unique mechanism of creating mote than 5 Lakh sample size consisting of Companies, Pharmacy Education, Trade, Investors & Doctors.

Originally launched in 1999 as the Pharma Business & Technology Excellence Awards, The Excellence Awards were first produced for the first time in India by the PHARMA BUSINESS & TECHNOLOGY MAGAZINE as a means of honoring innovation in pharmaceutical marketing, corporate governance, Research and development & Lifetime Achievements category. Pharma Excellence Awards were produced by PHARMA BUSINESS & TECHNOLOGY MAGAZINE Awards in India and expanded to recognize global corporate citizenship and individual achievements. Over the last one decade, Pharmaceutical business leadership awards 2012 has been re-evaluated and recast to focus more on business-scientific accomplishments in the biotech industry with a significant thrust in academic pharmaceutical research. The set of awards have been presented since last one decade at a sold-out gala to over 500 industry executives and leading academic scientists from around the world. Each Award or Nomination are being screened by the Board Members of Pharma Leaders Group consisting of 12 Member Team & than further approved by Network 7 Media Group Editorial Members from Pharmanewsprwire, Indian Affairs Juries consisting of eminent members of the Healthcare Community. After through screening, the names of four Nominees emerge out & are thrown out to public by E-mail Voting, Than SMS Voting followed by the final verdict of the Jury Members. The Awards demonstrate how companies can, through their core business activities, help achieve excellence in innovations. The 2012 Award Nominations has been given explicitly to companies delivering inclusive business models which are sustainable, commercially-viable business initiatives that expand access for low-income people to goods and services, or improve their livelihoods by engagement in value chains as direct employees, suppliers or distributors, while also generating sales and profit growth. By bringing together examples of innovative, effective business practices, 5th Annual Pharmaceutical Leadership Awards will also provide leading businesses and entrepreneurs with a valuable platform for networking and sharing experiences, and promote best practices. This will encourage other businesses and governments to replicate and scale initiatives. In 2011, the Awards received an unprecedented 172 nominations, representing a variety of business and commercial endeavors undertaken by business associations, non-governmental organizations and individual companies from more than 9 countries with a sample size of 5 Lakh 56 thousand & 674 voters spread across 21  states & 4 industry verticals via online, sms & physical interviews . “Past Award winners have shown how companies can help boost sustainable growth and development & they can be a tremendous source of innovative and sustainable solutions, which help transform people’s lives for the better." These Awards will highlight the critical role of the private sector in stimulating sustainable economic growth and development. A detailed Analysis of career graph/History or notable achievement is looked at to get the final four names. Such as
•             Financial management, 
•             Decision making roles and business impact.
·                     Business ethics.
•             Managing rapid growth.
•             Innovation.
•             Adapting to change.
•             Strategic partnerships.
•             Leadership roles.
•             Marketing strategies.
•             Corporate philanthropy to society.


The Award for the Best Return to Investors will be presented once the results for the Nomination process will end & the final vote count on 21st September. The Winner will be presented an Award Trophy & a certificate of Excellence.



Comments

Popular posts from this blog

India’s Economic Slowdown: Navigating Challenges with Resilience and how planetary alignments are suggesting an optimistic economic outlook

 By Aryan Prem Rana, Founder, VRIGHT PATH GROUP (www.vrightpath.com ) India, the world’s fastest-growing major economy, faces a challenging phase as GDP growth slows. The latest figures show Q2 growth dipping to 5.4%, the lowest in seven quarters. This decline comes as 63 of the Nifty 100 companies miss revenue estimates, raising concerns about underlying economic health. Growth Engines Sputtering The economic slowdown is most pronounced in key sectors: • Manufacturing growth has dropped to 2.2%, a sharp decline from last year’s 14.3%. • Urban consumption, a cornerstone of economic growth, is weakening. Industry stalwarts such as Reliance, HUL, and Maruti have seen market corrections of 15-23%. RBI’s Balanced Approach The Reserve Bank of India (RBI) has responded with measured policies, holding the repo rate steady at 6.5% for the eleventh consecutive meeting. This neutral policy stance balances inflation control with growth needs. In a key liquidity-boosting move, the RBI redu...

IMFA Reports Strong Q2 FY25 Financial Performance Driven by Higher Output and Operational Efficiency

  Indian Metals & Ferro Alloys Ltd (IMFA), India’s leading fully integrated producer of ferro alloys, announced robust financial results for the second quarter of FY25, ending on September 30, 2024. Financial Performance Highlights For Q2 FY25, IMFA reported strong standalone financial results: Revenue : ₹691.92 crore EBITDA : ₹175.62 crore, with a margin of 25.38% Profit After Tax (PAT) : ₹132.73 crore, achieving an 18.6% PAT margin Earnings Per Share (EPS) : ₹24.60 (not annualized) Exports : ₹652.97 crore This strong performance underscores IMFA's improved margins and profitability compared to the previous quarter, driven by higher production levels and operational efficiencies. Key figures from the company's half-yearly (H1 FY25) performance also reflect IMFA’s resilience in a challenging market, with a PAT of ₹250.25 crore and revenue totaling ₹1,354.2 crore. Operational Highlights IMFA’s operational metrics for Q2 FY25 demonstrated growth and stability: Ferro Chrome Pr...

ICE Make Reports 21.31% jump in consolidated revenue for Q2 FY2025

 Ice Make Refrigeration Limited (NSE: ICEMAKE), a leading innovator in cooling solutions and a prominent manufacturer of over 50 types of refrigeration equipment in India, has announced its financial results for the second quarter (Q2) of the fiscal year 2025, showcasing impressive growth and consistent performance across key financial metrics. Standalone Financial Performance The company reported a notable increase in revenue from operations, reaching ₹101.38 crores in Q2 FY2025. This represents a 21.88% jump compared to ₹83.17 crores in Q1 FY2025 and a significant 34% surge from ₹75.72 crores in Q2 FY2024. Total revenue also followed a similar upward trajectory, standing at ₹101.65 crores, up 21.89% quarter-on-quarter (QoQ) and 33.87% year-over-year (YoY). EBITDA for the quarter was recorded at ₹8.51 crores, marking an impressive 35.08% increase from ₹6.30 crores in the previous quarter and a 10.81% rise compared to ₹7.68 crores in Q2 FY2024. The EBITDA margin improved to 8.37%, ...